X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Nippon Kayaku will be responsible for regulatory approvals and commercialization of AB-106 (taletrectinib) for ROS1-positive NSCLC in Japan, and will have rights to further develop taletrectinib for new indications in the region.
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: AB-106
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AnHeart Therapeutics
Deal Size: Undisclosed Upfront Cash: $40.0 million
Deal Type: Licensing Agreement October 30, 2023
Details:
DARVIAS® (darinaparsin), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: Darvias
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Solasia Pharma KK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Under the license agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL and for marketing rights to darinaparsin.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: SP-02
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Solasia Pharma KK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
